과제정보
연구 과제 주관 기관 : Japan Society for the Promotion of Science
참고문헌
- Verbrugge FH, Dupont M, Steels P, et al. Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 2013;62:485-95. https://doi.org/10.1016/j.jacc.2013.04.070
- Rogler G, Rosano G. The heart and the gut. Eur Heart J 2014;35:426-30. https://doi.org/10.1093/eurheartj/eht271
- Nagatomo Y, Tang WH. Intersections between microbiome and heart failure: revisiting the gut hypothesis. J Card Fail 2015;21:973-80. https://doi.org/10.1016/j.cardfail.2015.09.017
- Sundaram V, Fang JC. Gastrointestinal and liver issues in heart failure. Circulation 2016;133:1696-703. https://doi.org/10.1161/CIRCULATIONAHA.115.020894
- Kamo T, Akazawa H, Suda W, et al. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One 2017;12:e0174099. https://doi.org/10.1371/journal.pone.0174099
- Sandek A, Swidsinski A, Schroedl W, et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol 2014;64:1092-102. https://doi.org/10.1016/j.jacc.2014.06.1179
- Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1561-9. https://doi.org/10.1016/j.jacc.2007.07.016
- Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol 2008;125:240-5. https://doi.org/10.1016/j.ijcard.2007.11.103
- Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41. https://doi.org/10.1056/NEJM199007263230405
-
Milani RV, Mehra MR, Endres S, et al. The clinical relevance of circulating tumor necrosis factor-
${\alpha}$ in acute decompensated chronic heart failure without cachexia. Chest 1996;110:992-5. https://doi.org/10.1378/chest.110.4.992 - Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7. https://doi.org/10.1161/01.CIR.102.25.3060
- Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-9. https://doi.org/10.1161/01.CIR.103.16.2055
-
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JTAnti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-
${\alpha}$ , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40. https://doi.org/10.1161/01.CIR.0000077913.60364.D2 - Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2
- Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838-42. https://doi.org/10.1016/S0140-6736(98)09286-1
- Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2003;5:609-14. https://doi.org/10.1016/S1388-9842(03)00104-1
- Li J, Jia H, Cai X, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol 2014;32:834-41. https://doi.org/10.1038/nbt.2942
- Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014;157:121-41. https://doi.org/10.1016/j.cell.2014.03.011
- Fischbach MA, Segre JA. Signaling in host-associated microbial communities. Cell 2016;164:1288-300. https://doi.org/10.1016/j.cell.2016.02.037
- Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369-79. https://doi.org/10.1056/NEJMra1600266
- Marchesi JR, Adams DH, Fava F, et al. The gut microbiota and host health: a new clinical frontier. Gut 2016;65:330-9. https://doi.org/10.1136/gutjnl-2015-309990
- Wang F, Li Q, Wang C, Tang C, Li J. Dynamic alteration of the colonic microbiota in intestinal ischemia-reperfusion injury. PLoS One 2012;7:e42027. https://doi.org/10.1371/journal.pone.0042027
- Phillips Campbell RB, Duffourc MM, Schoborg RV, et al. Aberrant fecal flora observed in guinea pigs with pressure overload is mitigated in animals receiving vagus nerve stimulation therapy. Am J Physiol Gastrointest Liver Physiol 2016;311:G754-62. https://doi.org/10.1152/ajpgi.00218.2016
- Pasini E, Aquilani R, Testa C, et al. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 2016;4:220-7. https://doi.org/10.1016/j.jchf.2015.10.009
- Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009;106:3698-703. https://doi.org/10.1073/pnas.0812874106
- Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 2016;22:1079-89. https://doi.org/10.1038/nm.4185
- Lekawanvijit S. Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities. Circ J 2015;79:2088-97. https://doi.org/10.1253/circj.CJ-15-0749
- Yang K, Wang C, Nie L, et al. Klotho protects against indoxyl sulphate-induced myocardial hypertrophy. J Am Soc Nephrol 2015;26:2434-46. https://doi.org/10.1681/ASN.2014060543
- Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011;472:57-63. https://doi.org/10.1038/nature09922
- Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-84. https://doi.org/10.1056/NEJMoa1109400
- Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014;124:4204-11. https://doi.org/10.1172/JCI72331
- Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014;64:1908-14. https://doi.org/10.1016/j.jacc.2014.02.617
- Tang WH, Wang Z, Shrestha K, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail 2015;21:91-6. https://doi.org/10.1016/j.cardfail.2014.11.006
- Troseid M, Ueland T, Hov JR, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med 2015;277:717-26. https://doi.org/10.1111/joim.12328
- Suzuki T, Heaney LM, Bhandari SS, Jones DJ, Ng LL. Trimethylamine N-oxide and prognosis in acute heart failure. Heart 2016;102:841-8. https://doi.org/10.1136/heartjnl-2015-308826
- Organ CL, Otsuka H, Bhushan S, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail 2016;9:e002314.
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-15. https://doi.org/10.1056/NEJMoa1205037
- Wang Z, Roberts AB, Buffa JA, et al. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 2015;163:1585-95. https://doi.org/10.1016/j.cell.2015.11.055
- Karbach SH, Schonfelder T, Brandao I, et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. J Am Heart Assoc 2016;5:e003698.
- Lam V, Su J, Koprowski S, et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012;26:1727-35. https://doi.org/10.1096/fj.11-197921
- Gan XT, Ettinger G, Huang CX, et al. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail 2014;7:491-9. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000978
- Marques FZ, Nelson EM, Chu PY, et al. High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 2017;135:964-77. https://doi.org/10.1161/CIRCULATIONAHA.116.024545
- Lekawanvijit S, Kompa AR, Manabe M, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 2012;7:e41281. https://doi.org/10.1371/journal.pone.0041281
- Costanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Probiotic therapy with Saccharomyces boulardii for heart failure patients: a randomized, double-blind, placebo-controlled pilot trial. Int J Cardiol 2015;179:348-50. https://doi.org/10.1016/j.ijcard.2014.11.034
- Zmora N, Zeevi D, Korem T, Segal E, Elinav E. Taking it personally: personalized utilization of the human microbiome in health and disease. Cell Host Microbe 2016;19:12-20. https://doi.org/10.1016/j.chom.2015.12.016
피인용 문헌
- The gut microbiome and heart failure vol.34, pp.2, 2017, https://doi.org/10.1097/hco.0000000000000598
- Critical symbiont signals drive both local and systemic changes in diel and developmental host gene expression vol.116, pp.16, 2019, https://doi.org/10.1073/pnas.1819897116
- Diet, the Gut Microbiome and Heart Failure vol.5, pp.2, 2019, https://doi.org/10.15420/cfr.2018.39.2
- The Revival of the Battle between David and Goliath in the Enteric Viruses and Microbiota Struggle: Potential Implication for Celiac Disease vol.7, pp.6, 2017, https://doi.org/10.3390/microorganisms7060173
- Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health vol.7, pp.1, 2017, https://doi.org/10.1186/s40168-019-0704-8
- Gut microbiota in coronary artery disease: a friend or foe? vol.40, pp.5, 2020, https://doi.org/10.1042/bsr20200454
- From obesity through gut microbiota to cardiovascular diseases: a dangerous journey vol.10, pp.1, 2017, https://doi.org/10.1038/s41367-020-0017-1
- The Intestinal Perspective of COVID-19: NOS2 and AOC1 Genes as Epidemiological Factors, and a Homeopathic Approach to their Functional Improvement vol.33, pp.3, 2020, https://doi.org/10.1055/s-0040-1715601
- Pulmonary fibrosis alters gut microbiota and associated metabolites in mice: An integrated 16S and metabolomics analysis vol.264, pp.None, 2017, https://doi.org/10.1016/j.lfs.2020.118616
- Intestinal Complication With Myxomatous Mitral Valve Diseases in Chihuahuas vol.8, pp.None, 2017, https://doi.org/10.3389/fvets.2021.777579
- The Correlation between Gut Microbiota and Serum Metabolomic in Elderly Patients with Chronic Heart Failure vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/5587428
- Risk Factors for Intestinal Barrier Impairment in Patients With Essential Hypertension vol.7, pp.None, 2017, https://doi.org/10.3389/fmed.2020.543698
- Gut–organ axis: a microbial outreach and networking vol.72, pp.6, 2017, https://doi.org/10.1111/lam.13333
- Sugar Fructose Triggers Gut Dysbiosis and Metabolic Inflammation with Cardiac Arrhythmogenesis vol.9, pp.7, 2021, https://doi.org/10.3390/biomedicines9070728
- Relationship between gut microbiota and markers of myocardial fibrosis in with chronic heart failure with preserved ejection fraction vol.20, pp.4, 2021, https://doi.org/10.15829/1728-8800-2021-2834